Valeo Pharma Inc (TSE:VPH) has released an update.
Valeo Pharma Inc. saw a modest revenue increase to $13.5 million in the first quarter of 2024, a 3% rise over the same period last year, alongside a slight improvement in adjusted EBITDA loss. The company’s asthma products led the charge with a significant prescription increase, but this was tempered by a decline in ophthalmology revenues. With various cost-saving initiatives in place, Valeo anticipates an upswing in revenue growth and improved margins in the upcoming quarters.
For further insights into TSE:VPH stock, check out TipRanks’ Stock Analysis page.
